# Dermatology

- [Atopic dermatitis](/content/dermatology/atopic-dermatitis/index.html)
- [Psoriasis](/content/dermatology/psoriasis/index.html)
- [Actinic keratosis](/content/dermatology/actinic-keratosis/index.html)
- [Acne](/content/dermatology/acne/index.html)
- Other skin conditions  
  - [Onychomycosis](/content/dermatology/onychomycosis/index.html)  
  - [Alopecia areata](/content/dermatology/alopecia-areata/index.html)  
  - [Keratinocyte cancer](/content/dermatology/keratinocyte-cancer/index.html)  
  - [Vitiligo](/content/dermatology/vitiligo/index.html)  
  - [Hidradenitis suppurativa](/content/dermatology/hidradenitis-suppurativa/index.html)  
  - [Rare skin diseases](/content/dermatology/rare-skin-diseases/index.html)

# Corporate actions and financing

## How we support our growth and strategy

In this section, we offer you a comprehensive view of the corporate actions and financing activities that underpin our long-term development at Almirall. These activities play an essential role in shaping our strategic direction, **ensuring financial stability, and supporting our commitment to research, innovation, and sustainable expansion.**

## Financial data

### Dividends evolution  
| Year | Gross amount per share (€) | Payment Date | Type |  
| --- | --- | --- | --- |  
| 2024 | 0.18 | 04/06/2025 | Ordinary |  
| 2023 | 0.18 | 05/06/2024 | Ordinary |  
| 2022 | 0.18 | 31/05/2023 | Ordinary |  
| 2021 | 0.19 | 01/06/2022 | Ordinary |  
| 2020 | 0.19 | 02/06/2021 | Ordinary |  
| 2019 | 0.19 | 01/10/2020 | Ordinary |  
| 2018 | 0.18 | 03/06/2019 | Ordinary |  
| 2017 | 0.19 | 01/06/2018 | Ordinary |  
| 2016 | 0.19 | 01/06/2017 | Ordinary |  
| 2015 | 0.19 | 01/06/2016 | Ordinary |  
| 2014 | 0.20 | 01/06/2015 | Ordinary |  
| 2012 | 0.15 | 05/06/2013 | Ordinary |  
| 2011 | 0.17 | 01/06/2012 | Ordinary |  
| 2010 | 0.28 | 01/06/2011 | Ordinary |  
| 2009 | 0.33 | 01/06/2010 | Ordinary |  
| 2008 | 0.31 | 01/06/2009 | Ordinary |  
| 2007 | 0.31 | 23/05/2008 | Ordinary |

## Our approach to financing

Financing is central to **maintaining momentum across our research pipeline, market operations, and international footprint**. We maintain a balanced approach to funding, focusing on stability, responsibility, and long-term resilience.

## Takeover bids

There are no takeover bids in process or operations with results announced less than one year ago.

## Debt issues

For information on current outstanding bonds you can access the LuxSE website.